Galvani Bioelectronics

Galvani Bioelectronics is a Stevenage, United Kingdom-based bioelectronics R&D company.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Galvani Bioelectronics is a Stevenage, United Kingdom-based bioelectronics R&D company.

History

It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016. The partnership to form the company was announced on 1 August 2016. Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.

The initial agreed upon investment between the two companies is up to £540 million over a period of seven years and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions." Additionally, both companies agreed to contribute their existing intellectual property rights.

In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1356499462 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

7 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.